The increasing importance of chronic rejection as a cause of renal allograft failure.
A consequence of reducing early graft failure due to acute rejection has been that more patients are at risk of chronic rejection, something which has become an increasingly important cause of graft loss. We examine the graft survival rates and reasons for failure in our unit from 1981 to 1986. Patients were divided into two series according to treatment of acute rejection episodes. From 1983 onwards, by treating acute vascular (poor prognosis) episodes with antilymphocyte globulin (ALG), we have significantly improved the 6-month actuarial graft survival rate. However, the percentage of total graft failure due to chronic rejection in this second series has significantly increased. The need for greater understanding of the aetiology of chronic rejection, together with its present unsatisfactory treatment, is discussed.
Dennis
M J
MJ
Department of Surgery, City Hospital, Nottingham, England.
Foster
M C
MC
Ryan
J J
JJ
Burden
R P
RP
Morgan
A G
AG
Blamey
R W
RW
D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003524:Cyclosporins / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D003524:Cyclosporins